Spinal Muscular Atrophy Advocacy Group Cure SMA Hails House’s Passage Of Access to Clinical Trials Act
The Ensuring Access to Clinical Trials Act of 2015 (EACT) has been passed by the U.S. House of Representatives, and…
Articles by Charles Moore
AveXis Secures $65 Million New Financing Earmarked To Advance Spinal Muscular Atrophy (SMA) Research
Dallas-based gene therapy platform company AveXis Inc., a leader in developing treatments for rare and life-threatening neurological genetic diseases, has…
Biogen Announces New EMBRACE Phase 2 Clinical Trial For SMA Drug
Biogen, a Cambridge, Massachusetts based developer, manufacturer and marketer of innovative therapies for patients living with serious neurological, autoimmune…
John Carbona Steps Down as AveXis CEO; Dallas Based AveXis Inc. Announces Management Succession Plan
Dallas, TX based AveXis has announced that company co-founder John Carbona has resigned from his position as CEO.
Cure SMA Announces $270,000 New Grant Funding for Spinal Muscular Atrophy Researchers
Cure SMA, an organization dedicated to the treatment and cure of Spinal Muscular Atrophy (SMA) — a severe and devastating…
Isis Pharmaceuticals Receives $7M Funding To Advance Clinical Trials Of ISIS-SMN Rx Spinal Muscular Atrophy Drug
Carlsbad, California-based Isis Pharmaceuticals, Inc. has received a $7 million milestone payment from Biogen Idec, to advance…
Cytokinetics and Astellas Expand Development Collaboration Of Skeletal Muscle Activators To Treat Muscular Atrophy, Other Neuromuscular Indications
South San Francisco based Cytokinetics, Incorporated and Astellas Pharma Inc. of Tokyo, Japan, have announced amendments expanding their…
Gene Therapy Delivered By Virus Shows Promise For Treating Spinal Muscular Atrophy (SMA)
Spinal Muscular Atrophy (SMA) is a genetic disorder that causes progressive muscle wasting and robs the afflicted of…